SURESNES, France, June 1, 2026
Servier has announced a landmark agreement to acquire Edgewise Therapeutics’ muscular dystrophy business in a transaction valued at up to $2.65 billion, significantly strengthening the company’s strategic position in rare neurological and neuromuscular diseases. The acquisition includes an upfront payment of $1.55 billion and up to $1.1 billion in regulatory and commercial milestone payments, underscoring Servier’s commitment to advancing innovative therapies for patients with severe and underserved disorders. Central to the transaction is sevasemten, a late-stage investigational therapy currently being evaluated in pivotal studies for Becker muscular dystrophy (BMD) and Phase 2 development for Duchenne muscular dystrophy (DMD). The deal aligns with Servier’s long-term Servier 2030 strategy, which focuses on expanding its presence in neurology through the development of transformative treatments for patients with significant unmet medical needs. The transaction, which has received approval from both companies’ governing bodies, is expected to close during the third quarter of 2026, pending regulatory clearance and customary closing conditions.
Sevasemten Offers Hope for Rare Neuromuscular Disorders
A key driver behind the acquisition is sevasemten, an investigational oral therapy designed as a first-in-class fast skeletal myosin inhibitor. The innovative treatment aims to preserve and protect unstable muscle fibers from contraction-induced damage, a hallmark of progressive muscular dystrophies. Becker muscular dystrophy and Duchenne muscular dystrophy are rare inherited genetic disorders characterized by progressive muscle degeneration, loss of mobility, and substantial reductions in quality of life. Becker muscular dystrophy currently has no approved treatment options, leaving patients with limited therapeutic alternatives as muscle weakness gradually worsens.
Duchenne muscular dystrophy, the most common and severe form of muscular dystrophy, typically begins in early childhood and often results in loss of ambulation during adolescence. By targeting the underlying mechanisms responsible for muscle damage, sevasemten has the potential to become a differentiated therapy capable of addressing critical unmet medical needs within both patient populations. The continued clinical advancement of this program could significantly alter the treatment landscape for neuromuscular diseases worldwide.
Strategic Acquisition Expands Servier’s Neurology Leadership
Advertisement
The acquisition represents a major strategic step for Servier as it continues to build a diversified portfolio of therapies targeting rare neurological conditions. In recent years, the company has increased investments in areas including epilepsy, autism spectrum disorders, movement disorders, and neuromuscular diseases. The addition of Edgewise Therapeutics’ muscular dystrophy business provides Servier with both a promising late-stage clinical asset and specialized expertise in muscle disease research and development.
Industry analysts view the transaction as a significant expansion of Servier’s neurology franchise, providing access to a potentially high-value therapeutic candidate with blockbuster potential in rare disease markets. The acquisition also demonstrates growing industry interest in rare genetic disorders, where scientific advances are creating new opportunities to develop targeted treatments for conditions that historically lacked effective therapies. By integrating Edgewise’s capabilities and development programs, Servier aims to accelerate innovation while strengthening its ability to bring transformative therapies to patients globally.
Growing Momentum in Rare Disease Innovation
Rare neuromuscular diseases remain among the most challenging therapeutic areas in modern medicine due to their genetic complexity, progressive nature, and limited treatment options. Advances in molecular biology, precision medicine, and targeted drug development are increasingly enabling companies to pursue therapies that directly address disease mechanisms rather than merely managing symptoms. The acquisition of Edgewise’s muscular dystrophy business reflects broader trends within the biopharmaceutical industry, where companies are investing heavily in rare disease innovation and specialty care markets.
For patients and healthcare providers, the transaction offers renewed optimism that next-generation therapies such as sevasemten may provide meaningful improvements in mobility, function, and long-term outcomes. As clinical development progresses, the program could emerge as one of the most important advancements in muscular dystrophy treatment in recent years. The deal further reinforces Servier’s ambition to become a global leader in rare neurology while highlighting the growing value of strategic acquisitions in accelerating the development and commercialization of breakthrough therapies.
Source: Servier, Edgewise Therapeutics press release
